EA-230 for Hospital Stay After CABG Surgery
This Phase III clinical trial is testing a new treatment called EA-230 for people having coronary artery bypass graft (CABG) surgery. EA-230 is given through an IV for 4 hours during surgery. Researchers want to see if EA-230 can help patients recover faster and reduce the amount of time they need to stay in the hospital after surgery, compared to a placebo (an inactive treatment). Earlier research suggested EA-230 might shorten hospital stays and reduce complications. You may be able to join if you are at least 18 years old and scheduled for elective CABG surgery with at least 3 bypasses. This study is currently unclear on its recruitment status.
- Study design
- This is a Phase III, double-blind, randomized, placebo-controlled study involving 300 participants. Neither you nor your doctors will know if you receive EA-230 or a placebo.
- What's involved
- You would receive EA-230 or a placebo intravenously for 4 hours during your CABG surgery.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your hospital length of stay will be measured for up to 28 days after surgery.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A Clinical Trial To Investigate The Effect Of EA-230 On Hospital Length Of Stay In Patients With Coronary Artery Disease (CAD) Undergoing Coronary Artery Bypass Grafting (CABG) Surgery.
At a glance
Conditions
Where it's being run
6 sites across 5 statesStudy leadership
- Peter Pickers, Prof. · PRINCIPAL_INVESTIGATOR · Radboudmc
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Required postoperative hospital length of stayUp to 28 days
Median postoperative duration, from the moment of first incision until the time when a patient is eligible to be discharged from the hospital.